Logo image of CVM

CEL-SCI CORP (CVM) Stock Fundamental Analysis

NYSEARCA:CVM - NYSE Arca - US1508376076 - Common Stock - Currency: USD

0.396  -0.03 (-6.38%)

After market: 0.3911 0 (-1.24%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CVM. CVM was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CVM has reported negative net income.
In the past year CVM has reported a negative cash flow from operations.
In the past 5 years CVM always reported negative net income.
CVM had a negative operating cash flow in each of the past 5 years.
CVM Yearly Net Income VS EBIT VS OCF VS FCFCVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

CVM has a Return On Assets of -102.18%. This is in the lower half of the industry: CVM underperforms 76.73% of its industry peers.
With a Return On Equity value of -214.34%, CVM is not doing good in the industry: 70.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -102.18%
ROE -214.34%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
CVM Yearly ROA, ROE, ROICCVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVM Yearly Profit, Operating, Gross MarginsCVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

CVM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CVM has been increased compared to 5 years ago.
CVM has a better debt/assets ratio than last year.
CVM Yearly Shares OutstandingCVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CVM Yearly Total Debt VS Total AssetsCVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CVM has an Altman-Z score of -28.49. This is a bad value and indicates that CVM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -28.49, CVM is doing worse than 90.41% of the companies in the same industry.
CVM has a Debt/Equity ratio of 0.62. This is a neutral value indicating CVM is somewhat dependend on debt financing.
CVM's Debt to Equity ratio of 0.62 is on the low side compared to the rest of the industry. CVM is outperformed by 76.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -28.49
ROIC/WACCN/A
WACCN/A
CVM Yearly LT Debt VS Equity VS FCFCVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.31 indicates that CVM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.31, CVM is not doing good in the industry: 84.19% of the companies in the same industry are doing better.
A Quick Ratio of 1.09 indicates that CVM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.09, CVM is doing worse than 85.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.09
CVM Yearly Current Assets VS Current LiabilitesCVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.22% over the past year.
EPS 1Y (TTM)29.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.81% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.35%
EPS Next 2Y19.14%
EPS Next 3Y20.44%
EPS Next 5Y25.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVM Yearly Revenue VS EstimatesCVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M 400M
CVM Yearly EPS VS EstimatesCVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVM Price Earnings VS Forward Price EarningsCVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVM Per share dataCVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as CVM's earnings are expected to grow with 20.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.14%
EPS Next 3Y20.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CEL-SCI CORP

NYSEARCA:CVM (2/21/2025, 8:11:25 PM)

After market: 0.3911 0 (-1.24%)

0.396

-0.03 (-6.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13
Earnings (Next)05-13 2025-05-13
Inst Owners10.25%
Inst Owner Change16.66%
Ins Owners2.94%
Ins Owner Change1.63%
Market Cap29.35M
Analysts80
Price Target7.55 (1806.57%)
Short Float %5.93%
Short Ratio3.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.18%
Min EPS beat(2)-6.63%
Max EPS beat(2)18.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.5%
EPS NY rev (3m)-0.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.28
P/tB 2.31
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.18%
ROE -214.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.09
Altman-Z -28.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.31%
Cap/Depr(5y)116.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y6.35%
EPS Next 2Y19.14%
EPS Next 3Y20.44%
EPS Next 5Y25.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year717.49%
EBIT Next 3Y181.37%
EBIT Next 5YN/A
FCF growth 1Y-22.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.26%
OCF growth 3YN/A
OCF growth 5YN/A